ProAxsis Transitions to Independent Growth Company to Advance Respiratory Research
A new fundraise will support commercial scale-up and the development of biomarker technology for respiratory disease drug development.
A new fundraise will support commercial scale-up and the development of biomarker technology for respiratory disease drug development.
Resmed has recommended corrections to certain Astral 100 and Astral 150 ventilators due to an issue that may result in interrupted therapy.
For patients in the pediatric ICU, pulse oximetry and waveform capnography are valuable tools to monitor the effectiveness of respiratory support and to inform treatment decisions.
American Lung Association is launching a new initiative to help the more than 16 million people in the US living with COPD manage symptoms and improve quality of life.
A phase 1 study is testing the safety of a microneedle device designed to deliver peanut protein through the skin for desensitization.
A study of more than 570,000 people validates a polygenic risk score to identify idiopathic pulmonary fibrosis patients at risk for severe outcomes or death.
A collaboration between Jiva.ai and Aevice Health has developed a predictive model that identifies potential asthma exacerbations up to 72 hours in advance.